Dashboard
Manage Tickers

ZYME Zymeworks Inc.

Nasdaq zymeworks.com


$ 18.04 $ -0.17 (-0.93 %)    

Wednesday, 05-Nov-2025 14:31:26 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 626.21 $ 7.76 (1.25 %)
DIA $ 473.80 $ 2.93 (0.62 %)
SPY $ 680.36 $ 5.32 (0.79 %)
TLT $ 88.96 $ -0.55 (-0.61 %)
GLD $ 366.55 $ 0.11 (0.03 %)
$ 18.16
$ 18.15
$ 18.02 x 11
$ 18.05 x 1
$ 17.97 - $ 18.40
$ 9.03 - $ 19.98
551,766
na
1.14B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-05-2025 01-01-1970 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5-analysts-have-this-to-say-about-zymeworks
5 Analysts Have This To Say About Zymeworks
10/24/2025 12:01:42

zymeworks-announces-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor-alpha-at-aacr-nci-eortc-conference
Zymeworks Announces Preliminary Results Fr...
10/23/2025 16:32:55

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced...

jp-morgan-maintains-overweight-on-zymeworks-raises-price-target-to-23
JP Morgan Maintains Overweight on Zymework...
10/16/2025 11:48:53

JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $20 to $23.

broadcom-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-tuesday
Broadcom To Rally More Than 12%? Here Are ...
10/14/2025 12:25:08

this-rpm-international-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday
This RPM International Analyst Turns Bulli...
10/14/2025 12:00:55

hc-wainwright--co-upgrades-zymeworks-to-buy-raises-price-target-to-26
HC Wainwright & Co. Upgrades Zymeworks to ...
10/14/2025 11:15:14

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks (NASDAQ:ZYME) from Neutral to Buy and raises the price targe...

zymeworks-to-present-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor--at-aacr-nci-eortc-conference-2025
Zymeworks To Present Preliminary Results F...
10/13/2025 20:02:36

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with ...

b-riley-securities-initiates-coverage-on-zymeworks-with-buy-rating-announces-price-target-of-30
B. Riley Securities Initiates Coverage On ...
10/10/2025 13:28:05

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating and announces Pri...

zymeworks-pulls-plug-on-early-stage-cancer-potential-as-therapy-unlikely-to-provide-benefit
Zymeworks Pulls Plug On Early-Stage Cancer...
09/02/2025 16:30:13

Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, includin...

zymeworks-discontinues-clinical-development-of-mesothelin-directed-t-cell-engager-zw171-following-phase-1-dose-escalation-review
Zymeworks Discontinues Clinical Developmen...
09/02/2025 10:06:15

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/22/2025 21:07:35

citigroup-maintains-buy-on-zymeworks-raises-price-target-to-22
Citigroup Maintains Buy on Zymeworks, Rais...
08/11/2025 13:00:44

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $19 to $22.

zymeworks-q2-eps-003-beats-049-estimate-sales-4873m-beat-1938m-estimate
Zymeworks Q2 EPS $0.03 Beats $(0.49) Estim...
08/07/2025 20:10:44

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

the-fda-has-cleared-zymeworks-investigational-new-drug-application-for-zw251-a-novel-glypican-3-targeted-adc-incorporating-the-companys-topoisomerase-1-inhibitor-payload-zd06519-for-hepatocellular-carcinoma-the-company-plans-to-start-phase-1-studies-for-zw251-in-2025
The FDA Has Cleared Zymeworks' Investigati...
07/28/2025 10:09:27

hc-wainwright--co-reiterates-neutral-on-zymeworks-maintains-13-price-target
HC Wainwright & Co. Reiterates Neutral on ...
07/03/2025 10:57:13

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $13 price target.

zymeworks-reveals-nmpa-approval-of-zanidatamab-in-china-for-adults-with-previously-treated-unresectable-or-metastatic-her2-high-expression-ihc3-biliary-tract-cancer-says-20m-milestone-payment-to-be-received-from-beone-medicines
Zymeworks Reveals NMPA Approval Of Zanidat...
05/30/2025 10:03:01

zymeworks-to-announce-presentations-highlighting-breadth-of-oncology-portfolio-at-asco-and-esmo-conferences
Zymeworks To Announce Presentations Highli...
05/22/2025 21:22:07

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodi...

td-securities-initiates-coverage-on-zymeworks-with-buy-rating
TD Securities Initiates Coverage On Zymewo...
05/20/2025 15:02:20

TD Securities analyst Yaron Weber initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating.

zymeworks-to-reveal-new-preclinical-data-for-zw1528-a-novel-il-4r-x-il-33-bispecific-molecule-designed-to-address-respiratory-inflammation-at-the-american-thoracic-society-international-conference-being-held-may-18-21-2025-in-san-francisco-ca
Zymeworks To Reveal New Preclinical Data F...
05/19/2025 20:18:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION